Stocktoria

NEOGEN CORP NEOG

Nasdaq · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 1989-08-23 · LEI

NEOGEN CORP (NEOG) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $870.4M at a -0.9% net margin.

Chart by TradingView
26/100
Stocktoria Quality Score · grade D
4/9
Piotroski F — financial health
-0.23
Altman Z″ — distress risk · distress
Dividend yield · no dividend
-2.63
Beneish M-score — earnings quality · low

Quality score trend · recomputed for each fiscal year

Piotroski F /9
4 6 4 4 3 5 3 5 4 6 2017201820192020202120222023202420252026
Altman Z″
14.59 16.41 18.08 17.12 17.34 14.78 3.41 3.46 -0.23 2.06 2017201820192020202120222023202420252026

Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.

$11.46 as of 2026-08-01 · +99.3% 1y
$5.71$12.0452-wk

Beneish M-score: -2.63 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.

Market cap USD$2.1B
Net margin 5y avg-23.5%
Return on equity 5y avg-9.7%
Beta1.8
Employees2,974

Analyst price target

$12.00 +4.7% vs last
consensus: buy · 3 analysts
target range $11.00 – $13.00

Wall Street analyst consensus — a sentiment gauge, not our scoring.

Smart money · insiders, last 12 months

Insiders net bought +$3,123 on the open market · 5 trades

Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.

Revenue trend · last 10y · up

How it ranks in Manufacturing · percentile among 1957 companies

Piotroski Fstronger than 45%
Net marginstronger than 51%
Return on equitystronger than 58%
Revenue growthstronger than 27%

Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 4/9 tests passed

Altman Z″ components · distress zone

ComponentValue
Working capital / assets0.117
Retained earnings / assets-0.156
EBIT / assets-0.308
Equity / liabilities1.509

Sector peers · similar-size Manufacturing companies compare side by side →

TickerCompanyPiotroski FAltman Z″P / ERevenue growth
NEOGNEOGEN CORP4/9-0.23-2.7%
MYGNMYRIAD GENETICS INC5/9-5.88-1.6%
LNTHLantheus Holdings, Inc.4/94.6130.6+0.5%
NTLAIntellia Therapeutics, Inc.2/9-6.12+16.9%
TKNOAlpha Teknova, Inc.5/9-1.59+7.4%
ICCCIMMUCELL CORP /DE/6/92.93+4.3%
NNNNAnbio Biotechnology4/9326.5

All Manufacturing companies →

About NEOGEN CORP

Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and complementary products to detect dangerous and unintended substances in human food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns, as well as food quality and nutritional components. It also provides software systems that help testers analyze and store results; natural toxin tests; rapid sanitation tests; culture and prepared media products; filter tests for microbial analysis of water; sample collection products; and food safety analysis laboratory services. This segment sells its products to the milling and grain, meat and poultry, ready-to-eat, fruits and vegetables, seafood, dairy, beverage, water, healthcare, traditional culture media markets, food service, and dietary supplements markets. Its Animal Safety segment provides reagents and test kits for use in immunoassay production, forensic and animal toxicology, and life science research, as well as colorimetric and chemiluminescent substrates; veterinary instruments and disposables; animal care and other products, including digestive aids and nutritional supplements; rodent and insect control products, and disinfectants; and genomics services, such as DNA genotyping, sequencing, and trait analysis for livestock and companion animals. This segment sells its products to companion animal veterinarians; livestock producers, veterinarians, and breed associations; retailers; breeding and genetics companies; diagnostic labs and universities; distributors; and other manufacturers and government agencies. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.

FAQ

Is NEOG financially healthy?

NEOGEN CORP's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.

Does NEOG pay a dividend?

No, NEOGEN CORP does not currently pay a dividend.

How profitable is NEOG?

In FY2025, NEOGEN CORP had a net margin of -0.9% and a return on equity of -0.4%.

Is NEOG overvalued or undervalued?

NEOGEN CORP trades at about 50.9× trailing earnings — below its 10-year norm (10-year range 74.1×–161.5×, median 117.2×). Stocktoria reports the data, not buy/sell advice.

What is the analyst price target for NEOG?

The average Wall-Street price target for NEOGEN CORP is $12.00, about 4.7% above the recent price, from 3 analysts (consensus: buy).

Is NEOG a good stock to buy?

Stocktoria doesn't give buy or sell advice, but here is the data on NEOGEN CORP: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.

Computed from company filings · US · as of 2025-05-31. Facts plus Stocktoria's own computed scores — not investment advice.